Pfizer (PFE)
(Delayed Data from NYSE)
$28.45 USD
-0.19 (-0.66%)
Updated Oct 25, 2024 04:00 PM ET
Pre-Market: $28.58 +0.13 (0.46%) 9:18 AM ET
3-Hold of 5 3
B Value F Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$28.45 USD
-0.19 (-0.66%)
Updated Oct 25, 2024 04:00 PM ET
Pre-Market: $28.58 +0.13 (0.46%) 9:18 AM ET
3-Hold of 5 3
B Value F Growth A Momentum C VGM
Zacks News
Nektar's (NKTR) Q2 Earnings Beat, Bempeg Makes Progress
by Zacks Equity Research
Nektar (NKTR) reports encouraging second-quarter 2020 results. The company continues to progress with its pipeline candidates.
Mylan (MYL) Q2 Earnings Beat Estimates, Revenues Fall Y/Y
by Zacks Equity Research
Mylan (MYL) beats on both earnings and revenues for the second quarter of 2020.
Bristol-Myers (BMY) Q2 Earnings Beat, 2020 Earnings View Up
by Zacks Equity Research
Bristol-Myers (BMY) beats on earnings and sales in the second quarter on the strength of Revlimid and Eliquis.
BioNTech (BNTX) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
During BioNTech's (BNTX) upcoming Q2 earnings conference, investors will keep track of the advancement of its COVID-19 vaccine candidate being developed in partnership with Pfizer.
Epizyme's (EPZM) Q2 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Epizyme (EPZM) reports a wider-than-expected loss and misses sales estimates in the second quarter of 2020.
The Zacks Analyst Blog Highlights: Eli Lilly, Moderna, Pfizer, Sanofi, GlaxoSmithKline and BioNTech
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Eli Lilly, Moderna, Pfizer, Sanofi, GlaxoSmithKline and BioNTech
3 Diverse Large-Cap Stocks to Buy Now to Boost Your Long-Term Portfolio
by Benjamin Rains
Investors should consider adding a few large-cap names that are prepared to grow for years to come. These three stocks also pay dividends and provide exposure to three very different and vital industries...
5 Growth ETFs & Stocks to Ride the Market Rally
by Sweta Killa
Growth investing has taken the lead over value and is likely to stay given a slew of reasons.
Pharma Stocks in Focus on Late-Stage Coronavirus Vaccine Trials
by Ritujay Ghosh
Hopes of a vaccine have once again started rising with a number of companies now entering the final phase of their trials.
Pharma Stock Roundup: Q2 Earnings & J&J and PFE's Coronavirus Updates in Focus
by Kinjel Shah
Pfizer's (PFE) coronavirus vaccine candidate enters phase III. Several drugmakers announce second-quarter results.
Coronavirus Vaccine Efforts Key to Moderna (MRNA) Q2 Earnings
by Zacks Equity Research
Moderna (MRNA) is progressing with coronavirus vaccine development. The company has initiated a late-stage study and investors will likely focus any preliminary data from the study
Glaxo (GSK) Q2 Earnings & Sales Miss Estimates, Decline Y/Y
by Zacks Equity Research
Glaxo (GSK) witnesses disruption from COVID-19 pandemic in Vaccines and reversal of stockpiling benefits from the first quarter in Pharmaceuticals and Consumer Healthcare, which hurt sales.
Stock Market News for Jul 29, 2020
by Zacks Equity Research
Benchmarks slipped into the negative territory on Tuesday as investors kept a close watch on a second coronavirus relief package in consideration by lawmakers, along with mixed second-quarter corporate earnings report.
Buy Caterpillar Stock Ahead of Q2 Earnings, Stay for the Dividend?
by Benjamin Rains
Caterpillar is set to release its second quarter fiscal 2020 financial results before the opening bell on Friday, July 31. Is it time to buy CAT stock?
3 Cheap Gold & Silver Stocks to Buy Right Now as Haven Prices Surge
by Benjamin Rains
It might be time for investors to take advantage of rising gold and silver prices. Let's dive into three such stocks trading under $20 per share that could be enticing...
Late-Stage Coronavirus Vaccine Trials Begin: Biotech ETFs to Gain
by Sweta Jaiswal, FRM
Two major vaccine developers' entrance into the final stage trials is expected to boost investor optimism.
Pfizer (PFE) Q2 Earnings Top, Sales Hurt by Coronavirus, View Up
by Zacks Equity Research
Pfizer (PFE) beats estimates for earnings while missing the same for sales. It slightly raises its financial outlook for the year.
All Eyes on "The Swamp;" Plus Q2 Reports from PFE, MCD & More
by Mark Vickery
Senate Republicans on Capitol Hill have unveiled their long-awaited stimulus package to replace the CARES Act, which expires at the end of this week. Also, the Fed begins a two-day session.
HEALS Act & Earnings Data Deluge
by Zacks Equity Research
HEALS Act & Earnings Data Deluge
The Zacks Analyst Blog Highlights: Facebook, Verizon Communications, Pfizer, Novartis and Philip Morris International
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Facebook, Verizon Communications, Pfizer, Novartis and Philip Morris International
Coronavirus Vaccine Development Puts These Stocks in Focus
by Ritujay Ghosh
Moderna and Pfizer launches two 30,000-subject trials of COVID-19 vaccines that could clear the way for regulatory approval and widespread use by the end of this year.
Pfizer (PFE) Q2 Earnings Surpass Estimates
by Zacks Equity Research
Pfizer (PFE) delivered earnings and revenue surprises of 21.88% and -0.63%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
COVID-19 Vaccine Push Brings Hope: Stock & ETF Beneficiaries
by Sanghamitra Saha
There are at least a hundred candidates in the COVID-19 vaccine race globally. However, few companies like Moderna, Pfizer and AstraZeneca are showing considerable hope.
Teladoc (TDOC) Q2 Earnings to Gain From Coronavirus-Led Demand
by Zacks Equity Research
Teladoc Health (TDOC) Q2 earnings are likely to have gained from higher virtual health visits and membership growth from coronavirus-led demand.
Sanofi (SNY) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Investor focus is likely to be on the impact of the coronavirus outbreak on Sanofi's (SNY) performance when it reports second-quarter results.